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Clara cell protein 16 (CC16) is a small protein mainly produced by non-ciliated Clara cells in the respiratory epithelium. 
It has an anti-inflammatory role in chronic upper and lower airway eosinophilic inflammations. Decreased levels of CC16 
are found in the nasal secretions and plasma of patients with chronic eosinophilic inflammatory disorders, such as asthma, 
allergic rhinitis, and chronic rhinosinusitis with or without nasal polyps, as well as in people exposed to high levels of 
air pollutants. Intranasal corticosteroid administration suppresses chronic inflammation of the nasal mucosa driven by 
eosinophils and stimulates local CC16 production. CC16 can be a reliable biomarker of the beneficial effects of perennial 
allergic rhinitis and chronic rhinosinusitis therapy and of the functional recovery of the nasal mucosa after treatment with 
topical glucocorticoids.
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ALLERGIC RHINITIS AND 
CHRONIC RHINOSINUSITIS: 
DEFINITION, CLASSIFICATION, AND 
PATHOPHYSIOLOGY
Allergic rhinitis
Allergic rhinitis (AR) is a non-infectious chronic 
inflammatory disease of the nasal mucosa mediated by 
immunoglobulin E (IgE) in response to allergen exposure. 
What plays an essential role in the development of AR is 
the imbalance between T helper 1 and T helper 2 (Th1/Th2) 
cells, where the inflammation-mediating Th2 cells prevail 
(1). The disease most often presents itself as a non-
infectious upper airway inflammation and affects between 
10 and 30 % of people in Western Europe and North 
America.
According to clinical characteristics, AR can be divided 
into seasonal and perennial. In patients with the seasonal 
allergic rhinitis (SAR), inflammation is most often triggered 
by the pollen of specific seasonal plants; hence the name 
“hay fever”. Which pollen shall trigger SAR will vary 
between individuals and regions, but it is generally caused 
by the tiny, barely visible pollens of wind-pollinated plants 
(2). Perennial AR (PAR), in turn lasts throughout the year 
and is a reaction to perennial allergens: house dust mites, 
fungi, animal dander, and such. It starts with the action of 
antigen-specific Th2 lymphocytes that secrete Th2 
cytokines, especially interleukin-4 (IL-4), IL-5, and IL-13, 
and is characterised by specific IgE in the early stage of 
allergic inflammation and secretory products in the late 
stage (3). These products, eosinophil cationic protein (ECP), 
major basic protein (MBP), and eosinophil peroxidases 
(EPOs) in particular, damage lamina propria (subepithelium) 
and cause localised oedema, resulting in the structural 
changes of the nasal mucosa (3). They seem to stimulate 
the so-called C-fibres and eventually nasal hyperreactivity, 
which is so characteristic for PAR. Henriquez et al. (4) 
clearly demonstrated higher permeability of cell membranes 
of cultured nasal epithelial cells following exposure to house 
dust mite antigens. Wise et al. (5) reported structural 
changes in intercellular junction proteins after prolonged 
exposure of nasal epithelial cells to Th2 cytokines (IL-4 
and IL-13), resulting in their increased permeability. These 
structural changes could explain some of the clinical signs 
of Th2-mediated sinonasal disease, such as oedema, nasal 
hypersecretion, and non-specific hyperreactivity (5).
According to the symptom frequency, AR can also be 
classified as intermittent and persistent. In intermittent AR 
symptoms occur less than four days a week over less than 
four weeks in a row. Persistent AR symptoms occur more 
than four days a week over more than four weeks.
According to the severity of clinical manifestations, AR 
can be divided into mild and moderate-to-severe. The 
symptoms are considered mild if they do not affect sleep 
or daily activities, including work or school. Moderate to 
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severe symptoms, however, disturb sleep, and affect daily 
activities (1).
Chronic rhinosinusitis
Chronic rhinosinusitis (CRS) is a very common 
inflammatory disease of the nasal and paranasal sinus 
mucosa with a duration of more than 12 weeks that can 
severely affect the quality of life. The most severe form is 
CRS with nasal polyps NPs (CRSwNP), characterised by 
frequent polyp recurrence despite medical and surgical 
therapy. Its exact aetiology and pathophysiology, however, 
remain unclear. The main characteristic of CRS is prolonged 
inflammation of the nasal and paranasal sinus mucosa. The 
inflammatory reaction is very important in the elimination 
of microbes, allergens, air pollutants, and other agents. 
However, it can also be harmful to the host, if the 
mechanisms regulating inflammatory mediator production 
are disturbed. A dysfunctional production of anti-
inflammatory mediators can lead to hyperinflammatory 
states and therefore exacerbate the chronic condition of the 
mucosa.
The pathogenesis of hypereosinophilia of the nasal 
mucosa in patients with PAR, CRSwNPs, and non-allergic 
rhinitis with eosinophilia syndrome (NARES) has been 
investigated poorly. A few studies showed an increased 
transendothelial migration of eosinophils, guided by 
chemokines in all chronic sinonasal eosinophilic 
inflammatory disorders (6, 7).
Eosinophil chemokines can be selective and non-
selective. Non-selective chemokines include regulated on 
activation normal T cell expressed and secreted (RANTES), 
macrophage inflammatory protein-1 alpha (MIP-1α), MIP-
1β, and monocyte chemoattractant proteins 1, 3, and 4 
(MCP-1, MCP-3, and MCP-4), as they attract not only 
eosinophils, but also monocytes, macrophages, and 
lymphocytes (7, 8). Selective chemokines, eotaxin-1, -2, 
and -3 attract only eosinophils via a specific CC chemokine 
receptor 3 (CCR3) (7).
ORIGIN AND FUNCTION OF THE CLARA 
CELL PROTEIN 16
The pseudostratified respiratory epithelium acts as the 
first line of defence against allergens, microbes, and air 
pollutant particles. To that effect, respiratory epithelium 
cells produce cytokines, chemokines, and other mediators 
of the immune system. Clara cells, also known as “club 
cells”, are non-ciliated secretory cells, situated among the 
ciliated cells of the columnar respiratory epithelium of the 
nasal cavity, paranasal sinuses, and tracheobronchial and 
bronchoalveolar parts of the airway. They modulate immune 
responses by secreting anti-inflammatory proteins (9). One 
of these anti-inflammatory and antioxidant proteins is the 
Clara cell protein 16 (CC16) with the molecular mass of 
only 16 kDa, also known as uteroglobin, secretoglobin-1a1, 
and club cell secretory protein (9). CC16 is secreted in the 
lining of the bronchoalveolar and nasal cavity and paranasal 
sinuses. It suppresses the activity of pro-inflammatory 
enzymes phospholipase A2 (PLA2) and transglutaminase, 
very important in arachidonic acid production and release 
during eosinophilic inflammation of the respiratory mucosa 
(9-11).
THE ROLE OF CC16 IN AR AND CRS
Johansson et al. (9) reported a negative correlation 
between the CC16 levels in nasal secretions and the severity 
of rhinitis symptoms in patients with SAR. In children with 
birch pollen-induced AR its levels in nasal fluid were 
reported lower than in subjects with healthy nasal mucosa, 
both before and during the pollen season (10). A similar 
finding of lower CC16 in serum and nasal discharge was 
reported in children with AR (11). In patients with PAR, 
nasal fluid CC16 positively correlated with nasal nitric oxide 
(NO) levels, and the two negatively correlated with mast 
cell counts in the nasal mucosal lining, which points to the 
protective role of both CC16 and NO, as they inhibit cell 
chemotaxis in chronically inflamed nasal mucosa (12). In 
an experimental investigation, Roth et al. (13) demonstrated 
that long-term exposure to perennial allergens caused most 
Clara cells to transform into large secretory goblet cells, 
which resulted in lower CC16 and higher mucus production 
in the bronchoalveolar mucosa. Studies with patients with 
PAR and CRSwNP demonstrated similar inhibition of CC16 
nasal mucosa production by eosinophil inflammation (11, 
14). One study (15) showed significantly lower mean CC16 
levels in the nasal secretions of patients with SAR, PAR, 
and (allergic and non-allergic) than controls whose nasal 
mucosa was not inflamed (15). In yet another study (16) 
CC16 immunoexpression in the mucosa of CRS patients 
with and without nasal polyps was significantly lower than 
in controls with healthy nasal mucosa. CC16 in plasma also 
negatively correlated with preoperative computed 
tomography (CT) scores and postoperative nasal endoscopy 
and symptom scores. Strong pro-inflammatory cytokines 
TNF-α, IL-1β and IL-4 inhibited, whereas anti-inflammatory 
cytokines IFN-γ and IL-10 promoted CC16 production in 
the nasal mucosa (16).
Different cytokines and chemokines regulate CC16 
expression in the nasal mucosa by modulating mRNA tissue 
expression (16, 17). The relationship between local mucosal 
production of eosinophilic chemokines and CC16 is very 
important for the development and further control of chronic 
inflammation. Previous investigations have demonstrated 
that eotaxins induce stronger transendothelial migration of 
eosinophils than of other eosinophilic chemokines (17-21). 
Shin et al. (22) reported inverse correlation between CC16 
and eotaxin-2 in the nasal secretion of PAR subjects. 
Eosinophils are attracted to the site of inflammation mainly 
by eotaxins and in smaller part by other, non-selective 
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eosinophil chemokines. The attracted and activated 
eosinophils, in turn, attract new eosinophils by synthesising 
more eotaxins. Activated eosinophils release high amounts 
of ECP and other toxic enzymes that affect nasal respiratory 
epithelium, including the Clara cells, which then leads to 
lower CC16 production. In contrast, CC16 inhibits 
eosinophil chemoattractant and Th2 cytokine (IL-4, IL-5, 
IL-13) production (23). In other words, there is a dynamic 
balance between the local production of eotaxin-2 and 
CC16, which is disturbed in patients with chronic 
eosinophilic nasal inflammation (21).
Nasal corticosteroid administration increases CC16 
levels in the nasal secretions of patients with PAR and in 
non-allergic and allergic patients with CRSwNP, but not in 
patients with SAR (15). In the nasal mucosa, glucocorticoids 
decrease the number of antigen-presenting cells, 
lymphocytes, mast cells, and eosinophils. Prolonged 
corticosteroid treatment suppresses the production of 
eosinophil chemoattractants and eosinophil infiltration in 
the nasal mucosa (24). This, in turn, lowers the release of 
toxic enzymes (ECP, MBP, and others) that damage the 
Clara cells. An interesting finding is the absence of any 
changes in CC16 levels in patients with SAR after nasal 
corticosteroid treatment. This phenomenon could be 
explained by strong seasonal variations in CC16 levels in 
the nasal secretions of SAR patients associated with specific 
seasonal allergens in the air.
CC16 AND PROLONGED EXPOSURE TO 
AIR POLLUTANTS
Current research has associated prolonged exposure to 
tobacco smoke (25), household heating with fossil fuels 
(wood in particular) (26), and chronic exposure to urban 
air pollutants (27) with decreases in CC16 levels in both 
serum and nasal secretions. Biagioni et al. (28) reported 
lower CC16 in nasal secretions and bronchoalveolar lavage 
in atopic individuals exposed to diesel exhaust. Although 
unknown, the mechanism leading to lower CC16 production 
could be similar to the one in cigarette smoking, which over 
time affects airway tissue repair. In an experimental study 
with rats, Xiao et al. (29) demonstrated that exposure to a 
mixture of air pollutants lowered CC16 mRNA expression 
initially, but also that it significantly increased after 30 days. 
They tried to explain this increase in CC16 with adaptation 
to prolonged unfavourable circumstances in which acute 
airway inflammation becomes chronic. However, CC16 can 
also increase during acute exposure. The case in point is 
the reaction of the airway epithelium to pollutant exposure 
in the swimming pools reported by Carbonnelle et al. (30). 
In trained swimmers, serum CC16 levels increased 
immediately after strenuous exercise, regardless of whether 
the pool water was treated with copper/silver or chlorine. 
They explained this acute increase in CC16 mucosal 
production with mechanical stress on the epithelial barrier 
caused hyperventilation during intense exercise.
CONCLUSIONS
CC16 is a strong anti-inflammatory protein that has an 
important role in the regulation of chronic eosinophilic 
inflammation of the nasal and paranasal sinus mucosa. 
Chronic eosinophilic upper airway inflammation, such as 
AR and CRSwNP, decreases CC16 production in the nasal 
mucosa. Intranasal corticosteroid administration directly 
suppresses local eosinophilic inflammation and stimulates 
local CC16 production. Similarly, most air pollutants 
suppress CC16 production in the nasal mucosa and 
bronchoalveolar epithelium.
CC16 can be a reliable biomarker of the efficacy of 
topical corticosteroid drugs in the treatment of chronic nasal 
inflammation and of the nasal mucosa recovery after the 
administration of topical corticosteroids. This protein may 
also be useful in estimating airway epithelium dysfunction 
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Razine proteina 16 Clara stanica u nosnoj sluznici tijekom alergijskog rinitisa, kroničnog rinosinuitisa i 
izloženosti onečišćenom zraku
Protein 16 Clara stanica (engl. Clara cell protein 16, krat. CC16) mali je protein kojega uglavnom stvaraju Clara stanice 
u respiratornom epitelu, koje nemaju cilije. Taj protein ima protuupalnu ulogu tijekom eozinofilnih upala gornjeg i donjeg 
dišnog puta. Niže koncentracije CC16 nađene su u nosnom sekretu i krvnoj plazmi pacijenata s kroničnim eozinofilnim 
upalnim bolestima, kao što su astma, alergijski rinitis i kronični rinosinuitis s nosnim polipima i bez njih, kao i u osoba 
koje su izložene onečišćenjima zraka. Primjena intranazalnih kortikosteroida blokira kroničnu eozinofilnu upalu nosne 
sluznice i stimulira lokalnu produkciju CC16. Protein CC16 može biti pouzdan biomarker ne samo poboljšanja funkcije 
nosne sluznice u pacijenata liječenih od perenijalnog alergijskog rinitisa i kroničnog rinosinuitisa nego i funkcionalnog 
oporavka nosne sluznice nakon terapije topikalnim glukokortikoidima.
KLJUČNE RIJEČI: glukokortikosteroidi; nosni polipi; posrednici upale
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